13F reference period
n/a
Security Snapshot
RAPT Therapeutics, Inc. - Common Stock, par value $0.0001 per share (RAPT) Institutional Ownership
CUSIP: 75382E109
13F Institutional Holders and Ownership History from Q4 2019 to Q1 2026
Institutions Reporting
Shares (Excl. Options)
n/a
Price
$1.04
The headline uses the Q2 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended.
Save this security page for your next review
Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, par value $0.0001 per share
- Symbol
- RAPT on Nasdaq
- Shares outstanding
- 27,725,634
- SEC-reported price per share
- $1.04
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source
Key facts
- RAPT - RAPT Therapeutics, Inc. - Common Stock, par value $0.0001 per share is tracked under CUSIP 75382E109.
- 13F reference-period holder data is not available.
- 11 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder data for the Q2 2026 reference period is not available.
- Available periods remain in the history table; they do not substitute for the headline period.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Schedule 13D/G
Open SEC evidence
Ownership context comes from Schedule 13D/G and available holder history for this CUSIP.
Security key
75382E109
13F reference period
n/a
13F holders
13D/G owners
11
CIK / CUSIP context first
RAPT full holder history
RAPT Therapeutics, Inc. SEC filings
RAPT Therapeutics, Inc. company facts
RAPT Therapeutics, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 75382E109:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
11
Security
RAPT
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Medicxi IV LP | 17% | $19,446,240 | 22,352,000 | Medicxi IV GP Limited | 27 Dec 2024 | |||
| Deep Track Capital, LP | 9.9% | $12,280,920 | 14,116,000 | Deep Track Capital, LP | 23 Dec 2024 | |||
| Redmile Group, LLC | 9.9% | $12,121,231 | 13,932,449 | Redmile Group, LLC | 31 Dec 2024 | |||
| TCG Crossover GP II, LLC | 10% | $11,478,006 | 13,193,110 | TCG Crossover GP II, LLC | 27 Dec 2024 | |||
| Foresite Capital Fund VI LP | 9.3% | $10,875,000 | 12,500,000 | Foresite Capital Fund VI, L.P. | 23 Dec 2024 | |||
| VANGUARD GROUP INC | 6.3% | +202% | $7,202,554 | +$4,651,367 | 8,278,798 | +182% | The Vanguard Group | 31 Mar 2025 |
| PERCEPTIVE ADVISORS LLC | 4.5% | $5,115,600 | 5,880,000 | Perceptive Advisors LLC | 31 Dec 2024 | |||
| BlackRock, Inc. | 1.7% | $2,006,761 | 2,306,622 | BlackRock, Inc. | 31 Mar 2025 | |||
| COLUMN GROUP II, LP | 4.9% | $1,395,126 | 1,603,593 | Peter Svennilson | 23 Dec 2024 | |||
| GLAZER CAPITAL, LLC | 5.4% | $50,334,004 | 1,486,094 | Glazer Capital, LLC | 02 Feb 2026 | |||
| FMR LLC | 0.4% | $418,041 | 480,507 | FMR LLC | 31 Jan 2025 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
26
Headline period
n/a
Rows shown
1-25 of 26
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 0 | $0 | -$100,346,899 | $1.04 | 0 |
| 2025 Q4 | 2,962,707 | $100,346,899 | -$332,096 | $33.87 | 3 |
| 2025 Q3 | 2,972,512 | $76,661,084 | +$42,075,407 | $25.79 | 3 |
| 2025 Q2 | 1,341,050 | $10,728,400 | -$158,903,455 | $8.00 | 2 |
| 2025 Q1 | 131,135,934 | $159,984,594 | +$4,424,695 | $1.22 | 89 |
| 2024 Q4 | 126,888,838 | $199,480,129 | +$130,912,564 | $1.58 | 89 |
| 2024 Q3 | 29,799,656 | $59,894,847 | -$5,399,235 | $2.01 | 92 |
| 2024 Q2 | 31,808,667 | $97,015,342 | -$20,514,565 | $3.05 | 100 |
| 2024 Q1 | 31,957,297 | $286,976,309 | -$135,887,644 | $8.98 | 120 |
| 2023 Q4 | 34,982,104 | $869,312,485 | +$6,735,986 | $24.85 | 108 |
| 2023 Q3 | 34,763,427 | $577,769,050 | +$11,319,522 | $16.62 | 96 |
| 2023 Q2 | 34,050,266 | $636,743,238 | +$14,411,769 | $18.70 | 97 |
| 2023 Q1 | 33,297,098 | $610,504,496 | +$19,762,513 | $18.35 | 104 |
| 2022 Q4 | 32,051,948 | $634,583,743 | +$67,138,151 | $19.80 | 92 |
| 2022 Q3 | 29,977,976 | $705,685,698 | -$6,718,488 | $24.06 | 96 |
| 2022 Q2 | 29,739,176 | $542,744,027 | +$30,137,398 | $18.25 | 83 |
| 2022 Q1 | 28,022,792 | $616,047,645 | -$11,376,493 | $21.99 | 82 |
| 2021 Q4 | 26,299,986 | $965,984,248 | +$58,612,650 | $36.73 | 96 |
| 2021 Q3 | 24,839,747 | $731,027,543 | +$65,328,555 | $31.05 | 104 |
| 2021 Q2 | 26,596,757 | $845,609,249 | +$179,542,242 | $31.79 | 107 |
| 2021 Q1 | 20,992,943 | $466,036,000 | +$14,749,147 | $22.20 | 77 |
| 2020 Q4 | 20,445,788 | $403,803,000 | +$1,193,976 | $19.75 | 80 |
| 2020 Q3 | 16,829,467 | $541,869,734 | +$65,277,706 | $32.20 | 66 |
| 2020 Q2 | 14,821,430 | $430,109,022 | +$93,891,523 | $29.02 | 52 |
| 2020 Q1 | 11,682,494 | $247,909,000 | +$53,863,363 | $21.27 | 37 |